Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 420.5 DKK -1.06% Market Closed
Market Cap: 29.9B DKK

Relative Value

The Relative Value of one ZEAL stock under the Base Case scenario is 99.48 DKK. Compared to the current market price of 420.5 DKK, Zealand Pharma A/S is Overvalued by 76%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ZEAL Relative Value
Base Case
99.48 DKK
Overvaluation 76%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
11
vs Industry
5
Median 3Y
107.5
Median 5Y
74.1
Industry
7
Forward
25.6
vs History
vs Industry
Median 3Y
-22.3
Median 5Y
-12.9
Industry
21.8
Forward
62.3
vs History
vs Industry
Median 3Y
-23
Median 5Y
-14.2
Industry
19.3
vs History
vs Industry
Median 3Y
-12.9
Median 5Y
-11.4
Industry
22.7
vs History
98
vs Industry
20
Median 3Y
9.6
Median 5Y
6.8
Industry
2.4
vs History
11
vs Industry
5
Median 3Y
101.1
Median 5Y
73.2
Industry
7.3
Forward
18.8
vs History
11
vs Industry
3
Median 3Y
88.4
Median 5Y
58.8
Industry
8.8
vs History
vs Industry
Median 3Y
-17.6
Median 5Y
-13.6
Industry
4
Forward
295.5
vs History
vs Industry
Median 3Y
-17.5
Median 5Y
-12.7
Industry
3.7
Forward
-13.6
vs History
vs Industry
Median 3Y
-21.1
Median 5Y
-12.2
Industry
4.5
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-11.4
Industry
3.2
vs History
50
vs Industry
8
Median 3Y
52.2
Median 5Y
24.5
Industry
4.5

Multiples Across Competitors

ZEAL Competitors Multiples
Zealand Pharma A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Zealand Pharma A/S
CSE:ZEAL
29.7B DKK 473.9 -27.5 -17.6 -17.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 893 126.3 -165 841.9 -201 384.9 -199 086.8
US
Abbvie Inc
NYSE:ABBV
328.4B USD 5.8 77.5 15.4 23.2
US
Amgen Inc
NASDAQ:AMGN
150.8B USD 4.5 36.9 15.2 26.9
US
Gilead Sciences Inc
NASDAQ:GILD
128.5B USD 4.5 267.8 10.6 13.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.1B USD 11.4 -235.5 25.8 27
US
Epizyme Inc
F:EPE
94.1B EUR 2 019 -515.2 -561 -546
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.9 27.3 16.9 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
65.7B USD 4.6 14.9 9.4 10.4
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.6 -64.2 -58
NL
argenx SE
XBRU:ARGX
32.4B EUR 16.8 44.3 -2 502.2 -1 677.6
P/S Multiple
Revenue Growth P/S to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average P/S: 3 172 335.6
473.9
205%
2.3
FR
Pharnext SCA
OTC:PNEXF
34 893 126.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.4
10%
1.1
US
E
Epizyme Inc
F:EPE
2 019
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.6
7%
0.7
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
16.8
37%
0.5
P/E Multiple
Earnings Growth PEG
DK
Zealand Pharma A/S
CSE:ZEAL
Average P/E: 78.1
Negative Multiple: -27.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 841.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.5
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
36.9
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
267.8
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -235.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.3
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.9
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
NL
argenx SE
XBRU:ARGX
44.3
28%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBITDA: 15.5
Negative Multiple: -17.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 384.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
15.2
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.8
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.4
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 502.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBIT: 20.3
Negative Multiple: -17.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 086.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.9
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.2
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.4
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 677.6 N/A N/A